🇺🇸 Lactobacillus Rhamnosus GG in United States

15 US adverse-event reports

Marketing authorisation

FDA

  • Status: approved

Safety signals — FAERS

Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.

Most-reported reactions

  1. Pneumonia — 3 reports (20%)
  2. Diarrhoea — 2 reports (13.33%)
  3. Fatigue — 2 reports (13.33%)
  4. Pancreatic Carcinoma — 2 reports (13.33%)
  5. Abdominal Discomfort — 1 report (6.67%)
  6. Abdominal Pain Upper — 1 report (6.67%)
  7. Anaemia — 1 report (6.67%)
  8. Aplastic Anaemia — 1 report (6.67%)
  9. Atrial Fibrillation — 1 report (6.67%)
  10. Back Pain — 1 report (6.67%)

Source database →

Lactobacillus Rhamnosus GG in other countries

Same drug, different regulators. Each page below lists the local marketing authorisation, HTA position, pricing, and adverse-event data.

Frequently asked questions

Is Lactobacillus Rhamnosus GG approved in United States?

Yes. FDA has authorised it.

Who is the marketing authorisation holder for Lactobacillus Rhamnosus GG in United States?

Madiha, MPhil is the originator. The local marketing authorisation holder may differ — check the official source linked above.